Grand Pharmaceutical Group Reports 15.1% Revenue Growth in 2022 Financials
China-based Grand Pharmaceutical Group Limited (HKG: 0512) published its 2022 financials, reporting revenues of HKD...
HKG: 0512
Grand Pharma’s First-in-Class RDC ITM-11 Accepted for IND Review
China-based Grand Pharmaceutical Group Ltd (HKG: 0512) has announced that an Investigational New Drug (IND)...
Grand Pharma Completes First Atrial Fibrillation Treatment with HeartLight X3
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the successful completion of the first...
Grand Pharma Completes Patient Enrollment for STC3141 Sepsis Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that all patients have completed enrollment...
Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND)...
Grand Pharma’s Jext Auto-Injector Approved for Import into Greater Bay Area
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced receiving official approval from the Guangdong...
China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs
The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round...
Grand Pharma’s COVID-19 Therapy GS221 Shows Promising Safety Profile
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its clinical study for the...
China Grand’s STC3141 Reaches Primary Endpoint in ARDS Phase Ib Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib clinical study...
Grand Pharma’s TLX591-CDx Approved for Prostate Cancer Diagnosis in China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Investigational New Drug (IND)...
Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...
Grand Pharmaceutical’s Carglumic Acid Set for Priority Review by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Grand Pharmaceutical Group Limited’s (HKG:...
China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512) published its financial results for the...
Grand Pharma’s TLX591-CDx and TLX250-CDx Advance in China with NMPA Review
Grand Pharmaceutical Group Limited (HKG: 0512) announced that the National Medical Products Administration (NMPA) has...
Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...
Grand Pharma Launches SIR-Spheres for Liver Cancer Treatment in China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the official launch of its SIR-Spheres...